Eugenio Marco et al. CALITAS: a CRISPR-Cas-aware ALigner for In silico off-TArget Search. Presented at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers meeting, August 18-20, 2021.

Dec

12

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec

9

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Nov

6

Editas Medicine to Participate in Upcoming Investor Conferences